A study found that typical cholesterol exams could be missing an important indicator of heart disease risk in certain people.

ApoB is emerging as a crucial piece of the heart health puzzle, even as sophisticated machines whir and beep with promises of ...

Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

Two blood tests you probably haven’t heard of might predict your risk of heart disease better than standard tests do. The ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...

“Many cardiovascular diseases caused by single gene variants are underdiagnosed because clinical sequencing is underused,” says Dan Rader, a physician-scientist heading the Division of ...

HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2-C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 ...

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.